Literature DB >> 23745034

Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.

Xiang-Shan Fan1, Jie-Yu Chen, Chang-Feng Li, Yi-Fen Zhang, Fan-Qing Meng, Hong-Yan Wu, An-Ning Feng, Qin Huang.   

Abstract

AIM: To investigate HER2 expression and its correlation with clinicopathological variables between proximal and distal gastric cancers (GC) in the Chinese population.
METHODS: Immunostaining of HER2 was performed and scored on a scale of 0-3 in 957 consecutive GC cases, according to the revised scoring criteria of HercepTest(TM) as used in the ToGA trial. Correlations between HER2 expression and clinicopathologic variables of proximal (n = 513) and distal (n = 444) GC were investigated.
RESULTS: Our results showed that HER2 expression was significantly higher in the proximal than in distal GC (P < 0.05). Overall, HER2 expression was significantly higher in male patients (P < 0.01), the Lauren intestinal type (P < 0.001), low-grade (P < 0.001) and pM1 (P < 0.01) diseases, respectively. There was a significant difference in HER2 expression among some pTNM stages (P < 0.05). In contrast, HER2 expression in the distal GC was significantly higher in male patients (P < 0.001), low-grade histology (P < 0.001), the Lauren intestinal type (P < 0.001), and pM1 (P < 0.001). In the proximal GC, however, higher HER2 expression scores were observed only in tumors with low-grade histology (P < 0.001) and the Lauren intestinal type (P < 0.001).
CONCLUSION: HER2 over-expression in GC of Chinese patients was significantly more common in proximal than in distal GC, and significantly correlated with the Lauren intestinal type and low-grade histology in both proximal and distal GC, and with pM1 disease and male gender in distal GC.

Entities:  

Keywords:  Clinicopathology; Gastric cancer; HER2; Immunohistochemistry

Mesh:

Substances:

Year:  2013        PMID: 23745034      PMCID: PMC3671084          DOI: 10.3748/wjg.v19.i21.3316

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.

Authors:  Stephen B Fox; Marian Priyanthi Kumarasinghe; Jane E Armes; Michael Bilous; Margaret C Cummings; Gelareh Farshid; Nicole Fitzpatrick; Glenn D Francis; Philip I McCloud; Wendy Raymond; Adrienne Morey
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients.

Authors:  Qin Huang; Xiangshan Fan; Agoston T Agoston; Anning Feng; Huiping Yu; Gregory Lauwers; Lihua Zhang; Robert D Odze
Journal:  Histopathology       Date:  2011-08       Impact factor: 5.087

3.  [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Authors:  J Rüschoff; I Nagelmeier; G Baretton; M Dietel; H Höfler; H U Schildhaus; R Büttner; W Schlake; O Stoss; H H Kreipe
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

4.  HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Authors:  Pamela L Kunz; Amirkaveh Mojtahed; George A Fisher; James M Ford; Daniel T Chang; Raymond R Balise; Charles D Bangs; Athena M Cherry; Reetesh K Pai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-01

5.  Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?

Authors:  Young Soo Park; Hee Sang Hwang; Hye Jin Park; Min-Hee Ryu; Heung-Moon Chang; Jeong Hwan Yook; Byung Sik Kim; Se Jin Jang; Yoon-Koo Kang
Journal:  Hum Pathol       Date:  2011-08-19       Impact factor: 3.466

Review 6.  HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.

Authors:  David G Hicks; Christa Whitney-Miller
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-12

7.  HER2 expression and its clinicopathological features in resectable gastric cancer.

Authors:  Yoshiki Kataoka; Hiroshi Okabe; Akihiko Yoshizawa; Sachiko Minamiguchi; Kenichi Yoshimura; Hironori Haga; Yoshiharu Sakai
Journal:  Gastric Cancer       Date:  2012-03-14       Impact factor: 7.370

8.  Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.

Authors:  Kab Choong Kim; Young Wha Koh; Heung-Moon Chang; Tae Hwan Kim; Jeong Hwan Yook; Byung Sik Kim; Se Jin Jang; Young Soo Park
Journal:  Ann Surg Oncol       Date:  2011-04-06       Impact factor: 5.344

Review 9.  Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review.

Authors:  Terence C Chua; Neil D Merrett
Journal:  Int J Cancer       Date:  2011-11-17       Impact factor: 7.396

10.  HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.

Authors:  Nicola Fusco; Elena Guerini Rocco; Claudia Del Conte; Caterina Pellegrini; Gaetano Bulfamante; Franca Di Nuovo; Solange Romagnoli; Silvano Bosari
Journal:  Mod Pathol       Date:  2013-01-25       Impact factor: 7.842

View more
  16 in total

1.  Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.

Authors:  Meltem Baykara; Mustafa Benekli; Ozgur Ekinci; Sultan Cigdem Irkkan; Halit Karaca; Umut Demirci; Muhammed Bulent Akinci; Olcun Umit Unal; Faysal Dane; Fatma Paksoy Turkoz; Ozan Balakan; Eylem Pinar Eser; Selcuk Cemil Ozturk; Metin Ozkan; Berna Oksuzoglu; Alper Sevinc; Necla Demir; Hakan Harputluoglu; Bulent Yalcin; Ugur Coskun; Aytug Uner; Ahmet Ozet; Suleyman Buyukberber
Journal:  J Gastrointest Surg       Date:  2015-07-16       Impact factor: 3.452

Review 2.  Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.

Authors:  Jan Trøst Jørgensen
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

3.  Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.

Authors:  Feng-Juan Gao; Jie-Yu Chen; Hong-Yan Wu; Jiong Shi; Ming Chen; Xiang-Shan Fan; Qin Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 4.  Unique Clinicopathology of Proximal Gastric Carcinoma: A Critical Review.

Authors:  Qin Huang
Journal:  Gastrointest Tumors       Date:  2014-07-18

Review 5.  Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review.

Authors:  Magdalena Tyczyńska; Paweł Kędzierawski; Kaja Karakuła; Jacek Januszewski; Krzysztof Kozak; Monika Sitarz; Alicja Forma
Journal:  J Gastrointest Cancer       Date:  2021-03-24

6.  Differences in Clinicopathology of Early Gastric Carcinoma between Proximal and Distal Location in 438 Chinese Patients.

Authors:  Qin Huang; Cheng Fang; Jiong Shi; Qi Sun; Hongyan Wu; Jason S Gold; H Christian Weber; Wenyan Guan; Yifen Zhang; Chenggong Yu; Xiaoping Zou; Hiroshi Mashimo
Journal:  Sci Rep       Date:  2015-08-27       Impact factor: 4.379

7.  Clinicopathological characterisation of small (2 cm or less) proximal and distal gastric carcinomas in a Chinese population.

Authors:  Qin Huang; Jiong Shi; Qi Sun; Jason S Gold; Jieyu Chen; Hongyan Wu; Huiping Yu; Yifen Zhang; Hiroshi Mashimo; Chenggong Yu; Travis Manasco; Wenyan Guan; Gregory Y Lauwers
Journal:  Pathology       Date:  2015-10       Impact factor: 5.306

8.  Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.

Authors:  Naoyuki Tominaga; Takuji Gotoda; Megumi Hara; Matthew D Hale; Takayoshi Tsuchiya; Jun Matsubayashi; Shin Kono; Chika Kusano; Takao Itoi; Kazuma Fujimoto; Fuminori Moriyasu; Heike I Grabsch
Journal:  Gastric Cancer       Date:  2015-05-19       Impact factor: 7.370

Review 9.  The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.

Authors:  Yu-Ying Lei; Jin-Yu Huang; Qiong-Rui Zhao; Nan Jiang; Hui-Mian Xu; Zhen-Ning Wang; Hai-Qing Li; Shi-Bo Zhang; Zhe Sun
Journal:  World J Surg Oncol       Date:  2017-03-21       Impact factor: 2.754

10.  Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections.

Authors:  Renato Santos Laboissiere; Marcelo Araújo Buzelin; Débora Balabram; Marina De Brot; Cristiana Buzelin Nunes; Rafael Malagoli Rocha; Mônica Maria Demas Álvares Cabral; Helenice Gobbi
Journal:  BMC Gastroenterol       Date:  2015-11-04       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.